← Back to Search

Pre-Surgery Radiation Boost for Breast Cancer

N/A
Recruiting
Led By Bruce G Haffty
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured 1-5 weeks prior to surgery and measured 1-7 weeks after surgery
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether delivering a part of the radiation treatment before surgery, when doctors can still visualize the tumor, may help to better target the tumor and decrease the volume of normal irradiated tissue.

Who is the study for?
This trial is for individuals with non-metastatic breast cancer, who are in good physical condition (ECOG 0-1), and have no signs of cancer spread. Pregnant women must test negative for pregnancy. Participants should be willing to follow the study protocol and haven't had prior chest radiation or chemotherapy.
What is being tested?
The trial studies the safety of a 'boost' dose of radiation given before surgery to target tumors more precisely, potentially improving cosmetic outcomes and tumor control. It includes quality-of-life assessments and MRI scans as part of evaluating this approach.
What are the potential side effects?
Potential side effects may include skin changes, fatigue, discomfort at the treatment site, swelling or scar tissue formation in the treated breast area. The boost aims to minimize normal tissue exposure but individual reactions can vary.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured 1-5 weeks prior to surgery and measured 1-7 weeks after surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured 1-5 weeks prior to surgery and measured 1-7 weeks after surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in wound status from baseline every 3-6 months after WBI to access incidence of grade 3 or more wound complications after breast conserving surgery.
Secondary study objectives
Physician reported cosmesis
Other study objectives
Acute and late radiation toxicity
Clinical target volume (CTV)
Patient reported cosmesis
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (radiation therapy boost, WBI)Experimental Treatment6 Interventions
Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Whole Breast Irradiation
2017
N/A
~160

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
449 Previous Clinical Trials
65,750 Total Patients Enrolled
15 Trials studying Breast Cancer
1,000 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,925 Previous Clinical Trials
41,017,946 Total Patients Enrolled
942 Trials studying Breast Cancer
1,443,237 Patients Enrolled for Breast Cancer
Bruce G HafftyPrincipal InvestigatorRutgers Cancer Institute of New Jersey

Media Library

Therapeutic Surgical Procedure Clinical Trial Eligibility Overview. Trial Name: NCT04871516 — N/A
Breast Cancer Research Study Groups: Treatment (radiation therapy boost, WBI)
Breast Cancer Clinical Trial 2023: Therapeutic Surgical Procedure Highlights & Side Effects. Trial Name: NCT04871516 — N/A
Therapeutic Surgical Procedure 2023 Treatment Timeline for Medical Study. Trial Name: NCT04871516 — N/A
~12 spots leftby Nov 2025